Thalidomide for treatment of multiple myeloma: 10 years later.
about
Current Trends of Renal Impairment in Multiple MyelomaVenous and arterial thrombotic risks with thalidomide: evidence and practical guidanceCarfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factorsThe Drug Repurposing Hub: a next-generation drug library and information resourceBendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data.Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.The successful treatment of hypercapnic respiratory failure with oral modafinil.Pimping up Drugs Recovered, Superannuated and Under Exploited Drugs - An Introduction to the Basics of Drug Reprofiling.Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.Inflammasome as a Therapeutic Target for Cancer Prevention and Treatment.Phase II trial of adjuvant oral thalidomide following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface disease from colorectal/appendiceal cancer.Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials.A cell-based fascin bioassay identifies compounds with potential anti-metastasis or cognition-enhancing functions.Sleep measured by polysomnography in patients receiving high-dose chemotherapy for multiple myeloma prior to stem cell transplantation.The use of novel agents in the treatment of relapsed and refractory multiple myelomaCyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myelomaThe prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea.Drug Repurposing for Cancer Therapy.Thalidomide and its analogues in the treatment of Multiple MyelomaImpact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma.Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010.Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study.Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.Role of thalidomide in previously untreated patients with multiple myeloma.Front line treatment of elderly multiple myeloma in the era of novel agents.In pursuit of the allo-immune response in multiple myeloma: where do we go from here?Emerging therapies targeting the ubiquitin proteasome system in cancerInitial therapy in multiple myeloma: investigating the new treatment paradigm.Current multiple myeloma treatment strategies with novel agents: a European perspectiveState-of-the-Art Management of Complications of Myeloma and Its Treatment.The Belgian 2010 consensus recommendations for the treatment of multiple myeloma.Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.Guidelines for supportive care in multiple myeloma 2011.Antineoplastic drug-induced bradyarrhythmias.
P2860
Q26740444-CC98A5F8-BD09-4702-9724-D2F3D032D2F7Q27008491-800F58E8-F8C3-4633-AE70-A6C294E268C8Q28084683-66266CC3-915B-48FB-96A8-88A7CD5DA641Q29363901-A410CB83-F7E1-4FD0-BBD2-7936697DA8DAQ30828090-FC279824-4D75-4875-A394-E2B30F3D88B0Q33389075-8E6C8DCD-51C0-4AB6-B8B0-5077DE430D06Q33398044-7E845F98-AD52-42B4-8CD3-EBA4A8FBA00BQ33568559-1649FAD8-50A1-49DA-9F53-A4A5A295B756Q33600352-B7970E99-0D7F-477C-8636-D3D0FDFD7B2AQ33632270-AF1F75C5-5D55-4149-81AB-D6536A6A2750Q33888059-E2EDCD96-CCE2-41BE-AC89-DEDC5BBAF796Q33940841-FA9D6112-864C-433A-B008-01F9A040A478Q33995471-79ACAFED-7F41-4762-A235-331758EA6498Q34372086-96A86599-0542-4D5E-A3C8-2B224DBCC481Q34392217-7337C1E5-DDD3-4488-878A-BFF1297E00E0Q35072925-F435DD44-0F4F-4A1E-B283-B6061F4BAC97Q35097319-0C2B5537-A26E-4986-8D75-89FA071D20B8Q35794472-5A22460B-7D27-4601-8C2D-49C4BD9FEBA0Q35907767-7EA6E0E7-2EDE-4153-83A9-5796DF64235CQ36081225-F83F1277-83D9-4B7A-9FDF-C2A9AC20BBCAQ36229392-19B5285C-9824-48B4-BD2E-AC0BA989B51FQ36444523-E1F2C660-8BDD-42E7-AAD1-1E88AD2F06C8Q36541807-3513FEC0-2B6A-43EB-B0A0-EF7EF03D5B78Q36697556-4C2C3CA7-7A5B-4D3A-9CEA-6F191745A928Q37082722-8E0C5E85-617E-4C81-B7E2-30AA25C85B6EQ37146672-0FDD11C3-34D9-47D7-8EAB-F3CA2943C344Q37248327-0FBE2098-C993-431D-8520-3BA168541D6EQ37300004-EDF300E7-DF2E-4E28-B023-CA4F33A71CEEQ37303213-3280AA74-6958-4514-AF90-FDCC36085DA4Q37349835-AAC63DF0-4F77-456E-94A1-F5B40567CEF5Q37410632-08D9D8DA-DE90-466B-8DE9-AB195A0C063EQ37411805-CBEC1F3D-DC60-490A-8A2A-F0565E15AF93Q37677935-1601123E-B542-4B9D-BAA9-EE2B3CA87CD7Q37776662-DD08AA4F-767E-4901-A4D0-30DCE9BD71C3Q37800884-66E1AA43-B2E3-4F91-A2D5-5ACC30F5BA0FQ37831402-34D7F013-C643-4ADA-911E-33B8E6A46710Q37842346-30E5F912-DFE1-4631-9421-53DBF62D5BE1Q37858523-9B9C8788-313E-489A-B4EB-96EFD1684A67Q37868637-D33D10E6-7D75-4AD9-811F-359DD10BBCB8Q38025714-89739951-FDD2-41E9-B624-C27F1B3069D0
P2860
Thalidomide for treatment of multiple myeloma: 10 years later.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Thalidomide for treatment of multiple myeloma: 10 years later.
@en
Thalidomide for treatment of multiple myeloma: 10 years later.
@nl
type
label
Thalidomide for treatment of multiple myeloma: 10 years later.
@en
Thalidomide for treatment of multiple myeloma: 10 years later.
@nl
prefLabel
Thalidomide for treatment of multiple myeloma: 10 years later.
@en
Thalidomide for treatment of multiple myeloma: 10 years later.
@nl
P2093
P50
P1433
P1476
Thalidomide for treatment of multiple myeloma: 10 years later.
@en
P2093
Anders Waage
Andrew Spencer
Francesca Gay
Jean-Luc Harousseau
Joan Bladè
Mario Boccadoro
Massimo Offidani
P304
P356
10.1182/BLOOD-2007-10-117457
P407
P577
2008-02-01T00:00:00Z